Skip to main content

ANIK

Stock
Health Care
Medical Instruments & Supplies

Performance overview

ANIK Price
Price Chart

Forward-looking statistics

Beta
0.53
Risk
41.15%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees363
Market cap$382.4M

Fundamentals

Enterprise value$123.8M
Revenue$117.1M
Revenue per employee—
Profit margin-48.48%
Debt to equity17.14

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.75
Dividend per share—
Revenue per share$8.01
Avg trading volume (30 day)$839K
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth+1.9
Credit+16.3
Liquidity-5.9
Inflation-0.4
Commodities+0.1
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-56.25
Price to sales1.38
P/E Ratio-56.25
Enterprise Value to Revenue1.06
Price to book1.09

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.

Zacks Investment Research (May 9, 2025)
Recap: Anika Therapeutics Q4 Earnings

Shares of Anika Therapeutics (NASDAQ:ANIK) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.09% year over year to $0.12, which beat the estimate of ($0.01).

Benzinga (March 4, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free